ARCT, NGM

Arcturus Therapeutics Holdings Inc. (ARCT)

Price (as of October 25)

14.86USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

ACLX

Arcellx, Inc.

-0.18

IKNA

Ikena Oncology, Inc.

-0.1

ACXP

Acurx Pharmaceuticals, Inc.

-0.08

DRUG

Bright Minds Biosciences Inc.

-0.06

GANX

Gain Therapeutics, Inc.

-0.05

IBRX

ImmunityBio, Inc.

-0.05

ACHL

Achilles Therapeutics plc

-0.05

ETTX

Entasis Therapeutics Holdings Inc.

-0.05

BCAB

BioAtla, Inc.

-0.05

AVTE

Aerovate Therapeutics, Inc.

-0.04

Show more

Highest within Industry

Symbol Correlation

ATAI

Atai Life Sciences N.V.

0.4

ALVR

AlloVir, Inc.

0.3

ALXO

ALX Oncology Holdings Inc.

0.26

AMLX

Amylyx Pharmaceuticals, Inc.

0.26

ALLO

Allogene Therapeutics, Inc.

0.24

ALLR

Allarity Therapeutics, Inc.

0.24

AMTI

Applied Molecular Transport Inc.

0.23

AMAM

Ambrx Biopharma Inc.

0.21

ALZN

Alzamend Neuro, Inc.

0.21

ATRA

Atara Biotherapeutics, Inc.

0.18

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company’s development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.